Protective cd8 memory t cell responses to mouse melanoma are generated in the absence of CD4 T cell help

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Côté, Anik L ^a   Byrne, Katelyn T ^a   Steinberg, Shannon M ^a   Zhang, Peisheng ^a   Turk, Mary Jo ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; LYMPHOCYTE DEPLETION; MALE; MELANOCYTE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; VITILIGO; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; EXPERIMENTAL MELANOMA; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; IMMUNOLOGIC MEMORY; MELANOMA, EXPERIMENTAL; MICE; T-LYMPHOCYTES;

EID: 84858786213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026491     Document Type: Article

References (49)

1. Cote AL, Usherwood EJ, Turk MJ, (2008) Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res 68: 1614-1617.
2. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, et al. (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782.
3. Zhang P, Cote AL, de Vries VC, Usherwood EJ, Turk MJ, (2007) Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 67: 6468-6476.
4. Byrne KT, Cote AL, Zhang PS, Steinberg SM, Guo Y, et al. (2011) Autoimmune melanocyte destruction is required for robust memory CD8+ T cell response to mouse melanoma. Journal of Clinical Investigation In Press.
5. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, et al. (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11: 1093-1101.
6. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102.
7. Shedlock DJ, Shen H, (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
8. Khanolkar A, Badovinac VP, Harty JT, (2007) CD8 T cell memory development: CD4 T cell help is appreciated. Immunol Res 39: 94-104.
9. Riberdy JM, Christensen JP, Branum K, Doherty PC, (2000) Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol 74: 9762-9765.
10. Marzo AL, Vezys V, Klonowski KD, Lee SJ, Muralimohan G, et al. (2004) Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol 173: 969-975.
11. Novy P, Quigley M, Huang X, Yang Y, (2007) CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol 179: 8243-8251.
12. Sun JC, Williams MA, Bevan MJ, (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5: 927-933.
13. Kemball CC, Pack CD, Guay HM, Li ZN, Steinhauer DA, et al. (2007) The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection. J Immunol 179: 1113-1121.
14. Wherry EJ, Ahmed R, (2004) Memory CD8 T-cell differentiation during viral infection. J Virol 78: 5535-5545.
15. Yi JS, Cox MA, Zajac AJ, (2010) T-cell exhaustion: characteristics, causes and conversion. Immunology 129: 474-481.
16. Sabarth N, Chamberlain L, Brett S, Tite J, Craigen J, (2010) Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen. J Immunol 185: 4590-4601.
17. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, et al. (2009) Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 69: 6256-6264.
18. Xiao H, Peng Y, Hong Y, Liu Y, Guo ZS, et al. (2011) Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J Immunol 187: 1788-1796.
19. Zelenay S, Demengeot J, (2006) Comment on "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells". J Immunol 177: 2036-2037; author reply 2037-2038.
20. Couper KN, Blount DG, de Souza JB, Suffia I, Belkaid Y, et al. (2007) Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol 178: 4136-4146.
21. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852-856.
22. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, et al. (2006) Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 176: 4632-4639.
23. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, et al. (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174: 2591-2601.
24. Hwang ML, Lukens JR, Bullock TN, (2007) Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol 179: 5829-5838.
25. Bos R, Sherman LA, (2010) CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70: 8368-8377.
26. Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, et al. (2009) Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183: 4848-4852.
27. Rabinovich GA, Gabrilovich D, Sotomayor EM, (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
28. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187-2194.
29. Jones ND, Carvalho-Gaspar M, Luo S, Brook MO, Martin L, et al. (2006) Effector and memory CD8+ T cells can be generated in response to alloantigen independently of CD4+ T cell help. J Immunol 176: 2316-2323.
30. Kmieciak M, Worschech A, Nikizad H, Gowda M, Habibi M, et al. (2011) CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat 126: 385-394.
31. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, et al. (2010) Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 70: 2665-2674.
32. Yu P, Lee Y, Liu W, Krausz T, Chong A, et al. (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201: 779-791.
33. Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, et al. (2009) Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 183: 7898-7908.
34. Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, et al. (2007) Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 179: 2860-2869.
35. Croce M, Corrias MV, Orengo AM, Brizzolara A, Carlini B, et al. (2010) Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer 127: 1141-1150.
36. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, et al. (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2: 1.
37. Shimizu J, Yamazaki S, Sakaguchi S, (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
38. Rice JC, Bucy RP, (1995) Differences in the degree of depletion, rate of recovery, and the preferential elimination of naive CD4+ T cells by anti-CD4 monoclonal antibody (GK1.5) in young and aged mice. J Immunol 154: 6644-6654.
39. Yi H, Zhen Y, Zeng C, Zhang L, Zhao Y, (2008) Depleting anti-CD4 monoclonal antibody (GK1.5) treatment: influence on regulatory CD4+CD25+Foxp3+ T cells in mice. Transplantation 85: 1167-1174.
40. Chace JH, Cowdery JS, Field EH, (1994) Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol 152: 405-412.
41. Wang LX, Li R, Yang G, Lim M, O'Hara A, et al. (2005) Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65: 10569-10577.
42. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907-912.
43. Kline J, Brown IE, Zha YY, Blank C, Strickler J, et al. (2008) Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 14: 3156-3167.
44. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, et al. (2009) Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 15: 1931-1939.
45. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, et al. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109: 4655-4662.
46. Bushell A, Morris PJ, Wood KJ, (1995) Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur J Immunol 25: 2643-2649.
47. Sharma MD, Hou DY, Baban B, Koni PA, He Y, et al. (2010) Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 33: 942-954.
48. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569-580.
49. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, et al. (1997) Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 71: 932-936.